Este artículo solo puede leerse en
pdf
Bibliografía
[1]
Pérez de Isla L, Bayes-Genis A, Sanchis J, Heras M..
Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales de la American Heart Association (Orlando Estados Unidos, 14-18 de noviembre de 2009)..
Rev Esp Cardiol. , (2010), 63 pp. 190-199
[2]
Pérez de Isla L, Bayes-Genis A, Sanchis J, Heras M..
Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales del American College of Cardiology (Atlanta Estados Unidos, 14-16 de marzo de 2010)..
Rev Esp Cardiol. , (2010), 63 pp. 695-707
[3]
Bayes-Genis A, Avanzas P, Pérez de Isla L, Sanchis J, Heras M..
Resumen de estudios clínicos presentados en el Congreso de 2010 de la European Society of Cardiology (28 de agosto-1 de septiembre de 2010, Estocolmo Suecia)..
Rev Esp Cardiol. , (2010), 63 pp. 1292-1303
[4]
Avanzas P, Pérez de Isla L, Bayes-Genis A, Sanchis J, Heras M..
Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales de la American Heart Association (Chicago Estados Unidos, 13-17 de noviembre de 2010)..
Rev Esp Cardiol. , (2011), 64 pp. e1-e8
[5]
Avanzas P, Pérez de Isla L, Bayes-Genis A, Sanchis J, Heras M..
Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales del American College of Cardiology (Nueva Orleans, Luisiana Estados Unidos, 2-5 de abril de 2011)..
Rev Esp Cardiol. , (2011), 64 pp. e1-e8
[6]
Avanzas P, Pérez de Isla L, Bayes-Genis A, Sanchis J, Heras M..
Resumen de estudios clínicos presentados en el Congreso de 2011 de la European Society of Cardiology (27-30 de agosto de 2011, París Francia)..
Rev Esp Cardiol. , (2011), 64 pp. e1-e8
[7]
Avanzas P, Pérez de Isla L, Bayes-Genis A, Sanchis J, Heras M..
Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales del American College of Cardiology (Chicago, Illinois Estados Unidos, 24-27 de marzo de 2012)..
Rev Esp Cardiol. , (2012), 65 pp. e1-e8
[8]
Avanzas P, Bayes-Genis A, Pérez de Isla L, Sanchis J, Heras M..
Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales de la American Heart Association (Orlando Estados Unidos, 12-16 de noviembre de 2011)..
Rev Esp Cardiol. , (2012), 65 pp. e1-e9
[9]
Diaz R, Ertl G. PURE: Prevalence, awareness, treatment and control of hypertension in 600 urban and rural communities from 17 high, middle and low income countries: Results from the PURE (Prospective Urban Rural Epidemiology). Available at: http://www.escardio.org/congresses/esc-2012/congress-reports/Pages/709-1-PURE.aspx..
[10]
Puymirat E, Simon T, Steg PG, Schiele F, Guéret P, Blanchard D, et al, for the USIK USIC 2000 and FAST MI Investigators. Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. JAMA. 2012 August 27. doi:10.1001/2012. jama.11348. Available at: http://jama.jamanetwork.com/article.aspx?articleid=1355142..
[11]
Lonn EM, Bosch J, Diaz R, Lopez-Jaramillo P, Ramachandran A, Hâncu N. for the GRACE and ORIGIN Investigators. GRACE: Effects of Insulin Glargin and of Polyunsaturated Fatty Acids on Carotid Intima Media Thickness in High-Risk. Diabetes. Available at: http://www.escardio.org/congresses/esc-2012/congress-reports/Pages/707-6-GRACE.aspx..
[12]
ALiskiren Trial In Type 2 Diabetes Using cardio-renal Endpoints. Available at: http://www.escardio.org/congresses/esc-2012/congress-reports/Pages/welcome.aspx..
[13]
Aoki T, Yosihiro Fukumoto Y, Yasuda S, Sakata Y, Ito K, Takahashi J, et al. The great East Japan earthquake disaster and cardiovascular diseases. Eur Heart J. 2012 August 28. doi: 10.1093/eurheartj/ehs288. Available at: http://eurheartj.oxfordjournals.org/content/early/2012/08/24/eurheartj.ehs288.full..
[14]
Roe MT, Armstrong PW, Fox KAA, White HD, Prabhakaran D, Goodman SG, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012 August 26. doi: 10.1056/NEJMoa1205512. Available at: http://www.nejm.org/doi/full/10.1056/NEJMoa1205512..
[15]
Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, et al. for the IABP-SHOCK II Trial Investigators. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012 August 27. doi: 10.1056/NEJMoa1208410. Available at: http://www.nejm.org/doi/full/10.1056/NEJMoa1208410?query=featured_home..
[16]
Min JK, Leipsic J, Pencina MJ, Berman DS, Koo BK, Van Mieghem C, et al. Diagnostic accuracy of fractional flow reserve from anatomic CT angiography. JAMA. 2012 August 26. doi:10.1001/2012.jama.11274. Available at: http://jama.jamanetwork.com/article.aspx?articleid=1352969..
[17]
Lima JA, Maurer G. CORE320: diagnostic performance of combined noninvasive coronary angiography and myocardial perfusion imaging using 320-row detector computed tomography: The CORE320 multicenter, multinational study. Available at: http://www.escardio.org/congresses/esc-2012/congress-reports/Pages/708-5- CORE320.aspx..
[18]
De Bruyne B, Pijls NHJ, Kalesan B, Barbato E, Tonino PAL, Piroth Z, et al. for the FAME 2 Trial Investigators. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012 August 28. doi: 10.1056/NEJMoa1205361. Available at: http://www.nejm.org/doi/full/10.1056/NEJMoa1205361?query=featured_home..
[19]
Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, et al. for the Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor. neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012 August 26. doi:10.1016/S0140-6736(12)61227-6. Available at: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61227-6/Abstract..
[20]
Aldosterone receptor blockade in diastolic heart failure. Available at: http://www.escardio.org/congresses/esc-2012/congress-reports/Pages/welcome.aspx..
[21]
Camenzind E, Wijns W, Mauri L, Kurowski V, Parikh K, Gao R, et al. for the PROTECT Steering Committee and Investigators. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet. 2012 August 27. doi:10.1016/S0140-6736(12)61336-1. Available at: http://www.thelancet.com/journals/lancet/article/PIIS0140-673.6(12)6133.6-1/Abstract..
[22]
Hamm C, Mohr F. for the ASTRID Investigators. GARY: German Aortic Valve RegistrY — in hospital outcome. Available at: http://www.escardio.org/congresses/esc-2012/congress-reports/Pages/707-3-ASTRID.aspx#discussant..
[23]
Schillinger W, Franzen O, Baldus S, Hausleiter J, Butter C, Schäfer U. on behalf of the ACCESS EUROPE Investigators. ACCESS-EUROPE - An observational study of the MitraClip® system in Europe. Available at: http://www.escardio.org/congresses/esc-2012/congress-reports/Pages/707-4-ACCESS-EU.aspx..
[24]
First randomised trial that compares two different regimens with and without aspirin in patients on oral anticoagulant therapy (OAC) undergoing coronary stent placement (PCI). Available at: http://www.escardio.org/congresses/esc-2012/congress-reports/Pages/welcome.aspx..
[25]
Widimský P, Budera P, Osmancík P, Vanek T, Jelínek S, Hlavicka J, et al. PRAGUE-12: Randomized open multicenter study comparing cardiac surgery with MAZE versus cardiac surgery without MAZE in patients with coronary and/or valvular heart disease and with atrial fibrillation. Available at: http://www.escardio.org/congresses/esc-2012/congress-reports/Pages/708-1-PRAGUE-12.aspx..
[26]
Brugada J, Arbelo A, Hindricks G, Maggioni A, Tavazzi L, Vardas P, et al. on behalf of the Atrial Fibrillation Ablation Pilot Study Investigators. AFib Ablation Pilot: ESC- EURObservational Research Programme: 1 -year follow-up of the atrial fibrillation ablation conducted by the European Heart Rhythm Association. Available at: http://www.escardio.org/congresses/esc-2012/congress-reports/Pages/708-3-Afib-Ablation-Pilot.aspx..